(Q35650600)

9 August 2017

title

Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) Study (English)

1 reference

9 August 2017

main subject

phase II clinical trial

0 references

1 reference

1 reference

1 reference

Katherine Y Look

1

1 reference

9 August 2017

Alan Sandler

2

1 reference

9 August 2017

John A Blessing

3

1 reference

9 August 2017

Joseph A Lucci

4

1 reference

9 August 2017

Peter G Rose

5

1 reference

9 August 2017

Gynecologic Oncology Group (GOG) Study

6

1 reference

9 August 2017

language of work or name

English

0 references

publication date

1 February 2004

1 reference

9 August 2017

1 reference

9 August 2017

volume

92

1 reference

9 August 2017

issue

2

1 reference

9 August 2017

page(s)

644-647

1 reference

Prognostic factors in early-stage uterine sarcoma. A Gynecologic Oncology Group study

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.11.023

Leiomyosarcoma of the uterus: clinicopathologic study of 21 cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.11.023

Resection of pulmonary metastases from uterine sarcomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.11.023

Surgery for pulmonary metastasis: a 20-year experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.11.023

A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.11.023

Phase II trial of ifosfamide and mesna in leiomyosarcoma of the uterus: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.11.023

Treatment of recurrent or advanced uterine sarcoma. A randomized trial of doxorubicin versus doxorubicin and cyclophosphamide (a phase III trial of the Gynecologic Oncology Group)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.11.023

Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcomas of the uterus: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.11.023

Preclinical characteristics of gemcitabine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.11.023

Phase II study of gemcitabine (2',2'-difluorodeoxycytidine) in previously treated ovarian cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.11.023

Mitoxantrone in the treatment of advanced uterine sarcoma. A phase II trial of the Gynecologic Oncology Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.11.023

A phase II clinical trial of diaziquone (AZQ) in the treatment of patients with recurrent leiomyosarcoma of the uterus. A Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.11.023

Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent uterine sarcomas: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.11.023

Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.11.023

Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.11.023

A phase I clinical, plasma, and cellular pharmacology study of gemcitabine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.11.023

10.1016/J.YGYNO.2003.11.023

7 January 2021

Identifiers

DOI

1 reference

9 August 2017

1 reference